Imidacloprid And Moxidectin

Verify with FDA CVM →

488 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
488
Total Reports
12
Deaths Reported
250.0%
Death Rate

Active Ingredients

Imidacloprid And Moxidectin

Administration Routes

TopicalOralUnknownOtherOphthalmic

Species Affected

Dog 303
Cat 164
Human 14
Unknown 6
Rabbit 1

Most Affected Breeds

Domestic Shorthair 101
Mixed (Dog) 42
Unknown 21
Domestic Longhair 20
Terrier - Yorkshire 19
Retriever - Labrador 19
Dog (unknown) 18
Cat (unknown) 17
Chihuahua 17
Maltese 14

Most Reported Reactions

Lethargy (see also Central nervous system depression in 'Neurological') 89
Pruritus 67
Vomiting 61
Behavioural disorder NOS 61
Ataxia 54
Other abnormal test result NOS 41
Hypersalivation 36
Diarrhoea 29
Muscle tremor 28
Application site alopecia 23
Inappetence 21
Anorexia 20

Outcome Breakdown

Outcome Unknown
242 (50.2%)
Recovered/Normal
220 (45.6%)
Died
8 (1.7%)
Ongoing
7 (1.5%)
Euthanized
4 (0.8%)
Recovered with Sequela
1 (0.2%)

Data Summary

Metric Value
Total adverse event reports 488
Reports involving death 12
Case-fatality rate (reported events) 250.0%
Distinct species in reports 5
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Imidacloprid And Moxidectin Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 488 adverse event reports referencing Imidacloprid And Moxidectin, including 12 reports in which the animal died — a 250.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Imidacloprid And Moxidectin. Reported administration routes include Topical, Oral, Unknown, Other. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Imidacloprid And Moxidectin reports are Dog (303 reports), Cat (164 reports), Human (14 reports), with Dog accounting for the largest share. Within those species, Domestic Shorthair (101), Mixed (Dog) (42), Unknown (21) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Imidacloprid And Moxidectin are Lethargy (see also Central nervous system depression in 'Neurological') (89), Pruritus (67), Vomiting (61), Behavioural disorder NOS (61). Of the 482 reports with a coded outcome, Outcome Unknown is the leading category at 50.2%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Imidacloprid And Moxidectin.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial